Video

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

Author(s):

Ritu Salani, MD,Ursula A. Matulonis, MD

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Related Videos
Elizabeth Buchbinder, MD
Brian A. Van Tine, MD, PhD
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Ritu Salani, MD
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Elias Jabbour, MD
Rena Callahan, MD, and Chandler Park, MD, FACP
Related Content
Ovarian Cancer
December 20th 2024

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Maximilian Stahl, MD
December 18th 2024

Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML

Premal Thaker, MD, MS, David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology, director, Gynecologic Oncology Clinical Research, interim chief, Division of Gynecologic Oncology, School of Medicine, Washington University in St. Louis, Siteman Cancer Center
November 11th 2024

Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS

stock.adobe.com
December 16th 2024

Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer

Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT
December 13th 2024

Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT